our services
Health Economics & Outcomes Research
Economic evidence to support the development and commercialization of novel treatments, devices, and diagnostics
Economic evidence to support the development and commercialization of novel treatments, devices, and diagnostics
Health Economics and Outcomes Research (“HEOR”) assesses the real-world value of pharmaceuticals, medical devices, diagnostics, and other healthcare interventions, considering the total impact of novel interventions on health outcomes, quality of life, and costs. AHE offers the full spectrum of economic evaluation services in support of the commercialization of novel biopharmaceuticals, medical technologies and devices, and diagnostics. Our HEOR team has decades of experience in developing economic evidence to support commercialization and market access in the U.S., Europe, Latin America, South America, and Asia. Our core capabilities are in the intersection of economic modelling and data analytics, bringing together strengths in conceptual models of value, disease progression modelling, and analysis of real-world evidence.
We serve a wide variety of clients throughout the U.S. and globally, including pharmaceutical companies, medical device and technology companies, diagnostic companies, and healthcare providers. We have applied our expertise in HEOR in a variety of settings and applications, including economic models for payer communications, modelling and evidence for HTA submissions, participation in advisory boards, collaboration on government grants and contracts, and publications in peer-reviewed journals.
Examples of engagements include:
Accurate and timely diagnosis is a critical component of global healthcare systems, driving a large proportion of clinical decision-making and resource use. Diagnostics can deliver value through multiple pathways, including (1) identifying patients who would benefit from treatment (i.e., screening for conditions and diseases); (2) identifying specific patients who would benefit the most from specific treatments (i.e., supporting “personalized medicine”); (3) differentiating between individuals presenting with similar sets of symptoms and data; (4) advances in diagnostic accuracy can lead to improvements in outcomes and efficiency; and (5) improvements in access and accuracy can facilitate more effective disease monitoring.
Read more...The use of cost-effectiveness methods to support policy decisions has become well established, but difficulties can arise when evaluating a new treatment that is indicated to be used in combination with an established backbone treatment. If the latter has been priced close to the decision maker's willingness-to-pay threshold, this may mean that there is no headroom for the new treatment to demonstrate value, at any price, even if the combination is clinically effective. Without a mechanism for attributing value to component treatments within a combination therapy, the health system risks generating negative funding decisions for combinations of proven clinical benefit to patients. In a 2025 publication in Value in Health, the Avalon team reported the results of a study to determine the best approach to attributing value to treatments provided in combination. The aim of the work was to define a value attribution methodology, which could be used to allocate value between the components of any combination treatment.
Read more...
We serve a wide variety of clients throughout the U.S. and globally, including pharmaceutical companies, medical device and technology companies, diagnostic companies, and healthcare providers. We have applied our expertise in HEOR in a variety of settings and applications, including economic models for payer communications, modelling and evidence for HTA submissions, participation in advisory boards, collaboration on government grants and contracts, and publications in peer-reviewed journals. Examples of engagements include:
.svg){kind=logo}